VA Changes Infliximab Biosimilars; Merck Formulary Win Could Drive Questions On Patient Switching
Move from one infliximab biosimilar to another could illuminate safety concerns surrounding non-medical switching – or at least Janssen hopes so; VA's national formulary moved from Remicade to Pfizer's Inflectra in 2017.
You may also be interested in...
CEO Craig Wheeler talked to Scrip about the challenging biosimilar market dynamics and the company's decision to end most biosimilar drug development. The path to value creation in biosimilars is not clear, he said.
As US FDA sees dip in application development, experts offer contrasting assessments about future of biosimilars at AAM's GRx Biosims conference.
Policymakers often frame the value of biosimilars in terms of how inexpensive they are, but sponsors use arguments that resemble those of their innovator counterparts.